γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors - Trial NCT06404281
Access comprehensive clinical trial information for NCT06404281 through Pure Global AI's free database. This Phase 1 trial is sponsored by Changzhou No.2 People's Hospital and is currently Not yet recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 9 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Changzhou No.2 People's Hospital
Timeline & Enrollment
Phase 1
Jun 01, 2024
Jun 01, 2026
Primary Outcome
Safety evaluation: Incidence of Adverse events (AEs),Safety evaluation: Dose limited toxicity (DLTs),Safety evaluation: Maximum-tolerated dose (MTD)
Summary
This study intends to combine the advantages of γδ T cells and PD-1 monoclonal antibody to
 conduct an exploratory clinical study on the safety and efficacy of PD-1 antibody armored γδ
 T cells (γδ T-PD-1 Ab cells) in the treatment of advanced solid tumors.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06404281
Non-Device Trial